• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Basic mechanisms and pathogenesis of venous thrombosis.静脉血栓形成的基本机制与发病机制。
Blood Rev. 2009 Sep;23(5):225-9. doi: 10.1016/j.blre.2009.07.002.
2
Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance.鉴定并功能表征与活化蛋白 C 抵抗相关的新型 F5 突变(Ala512Val,FVB onn)。
J Thromb Haemost. 2016 Jul;14(7):1353-63. doi: 10.1111/jth.13339. Epub 2016 Jun 13.
3
Pathophysiology of venous thrombosis.静脉血栓形成的病理生理学
Thromb Res. 2009;123 Suppl 4:S30-4. doi: 10.1016/S0049-3848(09)70140-9.
4
Factor V antigen levels and venous thrombosis: risk profile, interaction with factor V leiden, and relation with factor VIII antigen levels.凝血因子V抗原水平与静脉血栓形成:风险概况、与凝血因子V莱顿突变的相互作用以及与凝血因子VIII抗原水平的关系。
Arterioscler Thromb Vasc Biol. 2000 May;20(5):1382-6. doi: 10.1161/01.atv.20.5.1382.
5
Factor V and thrombotic disease: description of a janus-faced protein.凝血因子V与血栓性疾病:一种双面蛋白的描述
Arterioscler Thromb Vasc Biol. 2002 Apr 1;22(4):530-8. doi: 10.1161/01.atv.0000012665.51263.b7.
6
Activated protein C resistance--a major risk factor for thrombosis.活化蛋白C抵抗——血栓形成的主要危险因素。
Eur J Clin Chem Clin Biochem. 1997 Jul;35(7):501-16.
7
Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients.肿瘤来源的组织因子阳性微粒与癌症患者的静脉血栓形成。
Blood. 2013 Sep 12;122(11):1873-80. doi: 10.1182/blood-2013-04-460139. Epub 2013 Jun 24.
8
A novel factor V compound heterozygous mutation associated with thrombosis (Y1961C; FV-Kanazawa, together with 1982_1983del).一种与血栓形成相关的新型因子 V 复合杂合突变(Y1961C;FV-Kanazawa,同时伴有 1982_1983del)。
J Thromb Haemost. 2024 Oct;22(10):2810-2822. doi: 10.1016/j.jtha.2024.06.014. Epub 2024 Jun 29.
9
Genetic polymorphisms associated with venous and arterial thrombosis: an overview.与静脉和动脉血栓形成相关的基因多态性:综述
Arch Pathol Lab Med. 2002 Mar;126(3):295-304. doi: 10.5858/2002-126-0295-GPAWVA.
10
Polymorphisms in the protein C gene as risk factor for venous thrombosis.蛋白C基因多态性作为静脉血栓形成的危险因素。
Thromb Haemost. 2009 Jan;101(1):62-7.

引用本文的文献

1
Interventional Procedures in Deep Venous Thrombosis Treatment: A Review of Techniques, Outcomes, and Patient Selection.深静脉血栓形成治疗中的介入程序:技术、结果及患者选择综述
Medicina (Kaunas). 2025 Aug 18;61(8):1476. doi: 10.3390/medicina61081476.
2
Pulmonary Embolism in COVID-19: Trends from a Single-Center Study Across Ten Pandemic Waves in Romania.新型冠状病毒肺炎中的肺栓塞:罗马尼亚单中心十次疫情浪潮的趋势
Microorganisms. 2025 Jul 10;13(7):1634. doi: 10.3390/microorganisms13071634.
3
Current Antithrombotic Prescribing Habits for Extended Secondary Prevention in Patients with Peripheral Artery Disease and Unprovoked Venous Thromboembolism: A Survey Among Specialists in Angiology and Vascular Surgery.外周动脉疾病和不明原因静脉血栓栓塞患者二级预防的当前抗血栓处方习惯:血管病学和血管外科专家调查
J Clin Med. 2025 Jul 21;14(14):5157. doi: 10.3390/jcm14145157.
4
Humanized murine models of platelet function.血小板功能的人源化小鼠模型。
Curr Opin Hematol. 2025 Jul 14. doi: 10.1097/MOH.0000000000000879.
5
The APROVE (Anti-coagulation/Platelet Treatment in Pancreatic Resections Involving Vascular Reconstruction) Study: Results from a Worldwide Survey.APROVE(涉及血管重建的胰腺切除术的抗凝/血小板治疗)研究:一项全球调查的结果。
Ann Surg Oncol. 2025 Jun 30. doi: 10.1245/s10434-025-17686-y.
6
Recent Pathophysiological Insights Are Advancing the Treatment of Venous Thromboembolism.近期病理生理学见解推动了静脉血栓栓塞症的治疗进展。
JACC Basic Transl Sci. 2025 May;10(5):689-703. doi: 10.1016/j.jacbts.2024.12.004. Epub 2025 Feb 26.
7
The Type of Preoperative Oral Antithrombotics as a Risk Factor for Venous Thromboembolism After Hip Surgery: A Retrospective Study.髋关节手术后术前口服抗血栓药物类型作为静脉血栓栓塞危险因素的回顾性研究
Medicina (Kaunas). 2025 Apr 15;61(4):729. doi: 10.3390/medicina61040729.
8
Remnant cholesterol predicts risk of recurrent thrombosis beyond LDL-cholesterol in patients with antiphospholipid syndrome.在抗磷脂综合征患者中,残余胆固醇比低密度脂蛋白胆固醇更能预测复发性血栓形成的风险。
BMC Med. 2025 Apr 23;23(1):233. doi: 10.1186/s12916-025-04063-5.
9
Venous thrombosis unchained: Pandora's box of noninflammatory mechanisms.静脉血栓形成的非束缚状态:非炎症机制的潘多拉魔盒。
Blood Adv. 2025 Jun 24;9(12):3002-3013. doi: 10.1182/bloodadvances.2024014114.
10
Factor XI and XIa inhibition: a new approach to anticoagulant therapy.凝血因子XI及XIa抑制:抗凝治疗的新方法。
Br J Cardiol. 2024 May 14;31(2):018. doi: 10.5837/bjc.2024.018. eCollection 2024.

本文引用的文献

1
An update on clinical and basic aspects of the protein C anticoagulant pathway.蛋白 C 抗凝途径的临床和基础研究进展。
Trends Cardiovasc Med. 1995 Jul-Aug;5(4):141-8. doi: 10.1016/1050-1738(95)00054-D.
2
Valves of the deep venous system: an overlooked risk factor.深静脉系统瓣膜:一个被忽视的风险因素。
Blood. 2009 Aug 6;114(6):1276-9. doi: 10.1182/blood-2009-03-209981. Epub 2009 May 12.
3
The relationship between exercise and risk of venous thrombosis in elderly people.老年人运动与静脉血栓形成风险之间的关系。
J Am Geriatr Soc. 2008 Mar;56(3):517-22. doi: 10.1111/j.1532-5415.2007.01588.x. Epub 2008 Jan 4.
4
Venous thrombosis in the elderly: more questions than answers.老年人静脉血栓形成:问题多于答案。
Blood. 2007 Nov 1;110(9):3097-101. doi: 10.1182/blood-2007-06-096545. Epub 2007 Aug 7.
5
Venous thrombosis in the elderly.老年人静脉血栓形成
J Thromb Haemost. 2007 Jul;5 Suppl 1:310-7. doi: 10.1111/j.1538-7836.2007.02489.x.
6
Vascular bed-specific thrombosis.血管床特异性血栓形成
J Thromb Haemost. 2007 Jul;5 Suppl 1:283-91. doi: 10.1111/j.1538-7836.2007.02515.x.
7
Inherited thrombophilia and pregnancy associated venous thromboembolism.遗传性血栓形成倾向与妊娠相关静脉血栓栓塞症
BMJ. 2007 Jun 23;334(7607):1318-21. doi: 10.1136/bmj.39205.484572.55.
8
Increasing trends in waist circumference and abdominal obesity among US adults.美国成年人腰围和腹部肥胖呈上升趋势。
Obesity (Silver Spring). 2007 Jan;15(1):216-24. doi: 10.1038/oby.2007.505.
9
Inflammation and the activated protein C anticoagulant pathway.炎症与活化蛋白C抗凝途径。
Semin Thromb Hemost. 2006 Apr;32 Suppl 1:49-60. doi: 10.1055/s-2006-939554.
10
Risk of deep vein thrombosis and pulmonary embolism after acute infection in a community setting.社区环境中急性感染后深静脉血栓形成和肺栓塞的风险。
Lancet. 2006 Apr 1;367(9516):1075-1079. doi: 10.1016/S0140-6736(06)68474-2.

静脉血栓形成的基本机制与发病机制。

Basic mechanisms and pathogenesis of venous thrombosis.

作者信息

Esmon Charles T

机构信息

Oklahoma Medical Research Foundation, Howard Hughes Medical Institute, and Departments of Pathology and Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, United States.

出版信息

Blood Rev. 2009 Sep;23(5):225-9. doi: 10.1016/j.blre.2009.07.002.

DOI:10.1016/j.blre.2009.07.002
PMID:19683659
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2762278/
Abstract

In 1856 Virchow proposed a triad of causes for venous thrombosis, postulating that stasis, changes in the vessel wall or changes in the blood could lead to thrombosis. We now know that abnormally high levels of some coagulation factors and defects in the natural anticoagulants contribute to thrombotic risk. Among these, factor V Leiden, which renders factor Va resistant to activated protein C, is the most prevalent with approximately 5% of the Caucasian population having this genetic alteration. These genetically controlled variants in coagulation factors work in concert with other risk factors, such as oral contraceptive use, to dramatically increase thrombotic risk. While these abnormalities in the blood coagulation proteins are associated with thrombotic disease propensity, they are less frequent contributors to thrombosis than age or cancer. Cancer increases thrombotic risk by producing tissue factor to initiate coagulation, by shedding procoagulant lipid microparticles or by impairing blood flow. Age is the strongest risk factor for thrombosis. Among possible reasons are fragility of the vessels potentially contributing to stasis, increased coagulation factor levels, impaired function of the venous valves, decreases in the efficacy of natural anticoagulants associated with the vessel wall, increased risk of immobilization and increased risk of severe infection.

摘要

1856年,魏尔啸提出了静脉血栓形成的三联病因学说,假定血流淤滞、血管壁改变或血液变化可导致血栓形成。我们现在知道,某些凝血因子水平异常升高以及天然抗凝物质的缺陷会增加血栓形成风险。其中,导致因子Va对活化蛋白C产生抗性的凝血因子V莱顿突变最为常见,约5%的白种人有这种基因改变。这些凝血因子的基因控制变异与其他风险因素(如口服避孕药的使用)共同作用,显著增加血栓形成风险。虽然这些凝血蛋白异常与血栓形成疾病倾向有关,但与年龄或癌症相比,它们导致血栓形成的频率较低。癌症通过产生组织因子启动凝血、释放促凝脂质微粒或损害血流来增加血栓形成风险。年龄是血栓形成的最强风险因素。可能的原因包括血管脆弱可能导致血流淤滞、凝血因子水平升高、静脉瓣膜功能受损、与血管壁相关的天然抗凝物质功效降低、固定不动风险增加以及严重感染风险增加。